Hemab Therapeutics has announced the closing of an oversubscribed Series B financing.
The round was led by Access Biotechnology with participation from new investors Deep Track Capital, Avoro Ventures, Invus, Rock Springs Capital, and Maj Invest Equity. All current investors including HealthCap,